Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow

Affiliations

¹ Hématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMR 938, Paris, France.
² NYU Langone's Perlmutter Cancer Center, New-York, NY, USA.

Comment

Zoé Van de Wyngaert et al. Br J Haematol. 2022 Mar.

. 2022 Mar;196(5):1132-1133.

doi: 10.1111/bjh.17972. Epub 2021 Nov 25.

¹ Hématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMR 938, Paris, France.
² NYU Langone's Perlmutter Cancer Center, New-York, NY, USA.

No abstract available

Keywords: diagnostic haematology; flow cytometry; myeloma.

Comment on

Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry.
Clichet V, Harrivel V, Delette C, Guiheneuf E, Gautier M, Morel P, Assouan D, Merlusca L, Beaumont M, Lebon D, Caulier A, Marolleau JP, Matthes T, Vergez F, Garçon L, Boyer T. Clichet V, et al. Br J Haematol. 2022 Mar;196(5):1175-1183. doi: 10.1111/bjh.17933. Epub 2021 Nov 3. Br J Haematol. 2022. PMID: 34730236

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-57.
1. Paiva B, Puig N, Cedena M-T, Rosiñol L, Cordón L, Vidriales M-B, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784-92. https://doi.org/10.1200/JCO.19.01231
1. Goicoechea I, Puig N, Cedena M-T, Burgos L, Cordón L, Vidriales M-B, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021;137(1):49-60.